CDC25B and prostate neoplasm: With obvious growth-promoting properties, CDC25B over-expression has been demonstrated in a number of cancers including head, neck, gastric, ovarian, esophageal and prostate tumours, as well as non Hodgkin’s lymphoma (Broggini et al. 2000; Gasparotto et al. 1997; Hernandez et al. 1998; Kishi et al. 2002; Kudo et al. 1997; Miyata et al. 2000; Ngan et al. 2003).